SECOND PHASE OF COVAXIN HUMAN TRIAL BEING PLANNED AT SUM HOSPITAL

0 717

“The Phase I of the trial is still continuing as we are planning for the start of the Phase II trial shortly,”

Bhubaneswar( Kalinga Voice) : Preparations are underway at the Institute of Medical Sciences and SUM Hospital here for the commencement of the second phase of the human clinical trial of ‘Covaxin’, India’s indigenous Covid-19 vaccine.

     “The Phase I of the trial is still continuing as we are planning for the start of the Phase II trial shortly,” Dr. E.Venkata Rao, Principal Investigator of the trial at IMS and SUM Hospital, faculty of medical sciences of the SOA Deemed to be University, said.

     The blood samples collected from the volunteers who received the vaccine wereto ascertain how effective the vaccine was in terms of the level of antibodies developed, Dr. Rao said adding that there had been ‘no side effects’ in the first phase trial.

     The IMS and SUM Hospital is one of the 12 medical centres in India chosen by the Indian Council for Medical Research (ICMR) for conducting human trial of the vaccine developed by Hyderabad-based Bharat Biotech as the Coronavirus was spreading in the country fast.It is the only medical center chosen in Odisha for the trial.

     “Two doses of the vaccine were administered to each volunteer after they were selected through a screening process conducted over a period of three to seven days prior to vaccination. The first dose was administered on Day Zero while the blood sample was collected. The second dose was given on Day 14 and the blood sample was also collected,” Dr. Rao said.

     Blood samples of the volunteers will also be collected on different days  (28, 42, 104, 194 day) for estimating the duration of protection subsequently, he added.

     Dr. Rao said there was a lot of enthusiasm among people to be part of the second phase of the human trial. Those who wish to be part of this trial could contact the centre at http://ptctu.soa.ac.in.

Leave A Reply

Your email address will not be published.